The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Novel agents in development for the treatment of MCL
In this video, Nilanjan Ghosh, MD, PhD, Atrium Health Levine Cancer Institute, Charlotte, NC, shares some insights into novel agents being investigated for the treatment of mantle cell lymphoma (MCL). Dr Ghosh first comments on the promise of pirtobrutinib, which is currently being investigated in clinical trials. Dr Ghosh then discusses the promise of novel immunotherapies, including bispecifics, CAR-T therapy, and ROR1-targeting antibodies. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Research funding, honoraria, consulting: BMS
Consulting: Lilly, Genentech/Roche
